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Avoiding the inhibitory effects of p53 on cell growth is important for tumor progression. In this issue ofCancer
Cell, Picchiorri et al. describe epigenetic silencing of MDM2-targeting microRNAs in multiple myeloma (MM),
which generally appears to have intact p53 function. This provides the rationale for microRNA-targeted
therapy for MM.Genetically,multiplemyeloma (MM)canbe
divided into tumorswith recurrent immuno-
globulinheavychaingene translocationsor
hyperdiploidy. Superimposed on this are
a variety of presumably secondary genetic
events, including activating mutations of
Ras, rearrangements of Myc, mutations
thatactivate theNFkBpathway,and late in-
activatingmutations of p53 (Fonseca et al.,
2009). As noted by Pichiorri et al., (2010),
mutations of p53 are rare in untreated
MM and the tumors appear to have intact,
if perhaps suppressed, p53 function, sug-
gesting that therapeutic modulation of the
p53/MDM2 pathway holds promise to
help the majority of patients.
Deletion of one copy of p53 by FISH has
been uniformly found to be an adverse
prognostic factor with all therapies used
in the treatment of MM: alkylating agents,
proteasome inhibitors, and immune
modulator-based therapies (Lode’ et al.,
2010; Kapoor et al., 2010). In contrast
to patients with other poor-prognosticgenetic lesions [e.g., t(4;14)], patients
with deletion of p53 have seen less
improvement in their survivalwith theaddi-
tion of proteasome inhibitors and immune
modulators. Nevertheless, data concern-
ing loss of heterozygosity of p53 due to
deletion of chromosome 17p and/or p53
mutation in MM have been confusing,
perhapsat least inpartbecauseofold liter-
ature based on the analysis of unpurified
bone marrow samples. In an analysis of
CD138-purified myeloma cells from 716
patients, deletion of one copy of p53
was detected by FISH in 3% of MGUS
(monoclonal gammopathy of undeter-
mined significance), 1% of SMM (smol-
dering multiple myeloma), and 10% of
MM (Chiecchio et al., 2009). There is a
paucity of data on patients at the time of
relapse; however, in another recent study,
deletionof p53wasseen in 56%ofprimary
plasma cell leukemia and 83%of themore
aggressive secondary plasma cell
leukemia (Tiedemann et al., 2008).Somewhat surprising, given the
strong correlation between loss of one
copy of p53 deletion and survival, is
the fact that in a cohort of 92 untreated
MM patients, only 37% of patients with
p53 deletions by FISH were found
to have mutations on the remaining allele,
although all those with mutations were
found to also have p53 deletions (Lode’
et al., 2010). It would be very informative
to characterize whether in terminal
samples from patients that initially pre-
sented with a 17p deletion by FISH,
a p53 mutation has emerged under the
selective pressure of therapy and disease
progression. In the absence of such
a study, we can examine the status of
p53 in a panel of human MM cell lines
derived from patients at the very end
stages of the disease. It is notable that
the majority of MM cell lines have p53
mutation (Mazars et al., 1992). Although
one has to consider that cell lines have
been under the selective pressure of being, October 19, 2010 ª2010 Elsevier Inc. 299
miR-192-194-215
Figure 1. Illustration of the p53–miR-192,194,215–MDM2 Auto
Regulatory Loops
An illustration of the p53–miR-192,194,215–MDM2 auto regulatory loops
showing the central role played by the miRs in determining the balance of
p53 suppressor and the MDM2 oncoprotein expression levels (adapted from
Pichiorri et al., 2010).
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Previewsable to grow ex vivo, these
data strongly argue that is
the ultimate inactivation of
p53 that underlies the poor
prognosis associated with
the initial loss of one copy.
What is clear from all these
studies and in the absence
of more definitive sequencing
data is that the great majority
of patients seems to retain
an intact p53 pathway and
may therefore be susceptible
to its successful modulation.
One well-characterized way
by which p53 is modulated
is the E3 ubiquitin ligase
MDM2, and more recent
studies have identified that
microRNAs 29 and 125a
target p53 and members of
its pathway (Park et al.,
2009; Zhang et al., 2009). In
order to determine the path-
ways relevant to MM, Pi-
chiorri et al. start their anal-
ysis by identifying in MM cell
lines the p53-regulated miR-
NAs miR-192, 194, and 215
(Pichiorri et al., 2010). Key tothese studies is a panel of genetically
characterized MM cell lines with and
without inactivating mutations of p53.
They determine that these miRs are
direct transcriptional targets of p53, and,
intriguingly, they find that the miRs
are expressed at a lower level in MM
than MGUS and are associated with pro-
moter hypermethylation in MM cell lines
(Figure 1). They show that expression of
these miRs induces a cell cycle arrest in
a p53-dependent manner and, noting
lower levels of MDM2, they go on to
show that these miRs directly target
MDM2, with the expected downstream
effects on IGF1 and IGF1R migration
and invasion.300 Cancer Cell 18, October 19, 2010 ª2010So how close are we to miR replace-
ment therapy for MM? The authors do
not conjecture, and they leave a few other
questions unanswered. They postulate,
but do not demonstrate, that aberrant
promoter methylation is responsible for
silencing of these miRs during the transi-
tion from MGUS to MM. They suggest
a gradient effect of p53 function that in
patients with 17p deletion is modulated
by haploinsuffiency. During tumor pro-
gression, due to a partial loss of expres-
sion of regulatory miRs, presumably this
is sufficient to allow intramedullary tumor
growth in vivo but, as noted above, is
presumably insufficient to allow in vitro
tumor growth as MM cell lines. TheseElsevier Inc.studies provide the rationale
for the development of thera-
pies to supplement inappro-
priately suppressed miR ex-
pression in MM.REFERENCES
Chiecchio, L., Dagrada, G.P.,
Ibrahim, A.H., Dachs Cabanas, E.,
Protheroe, R.K., Stockley, D.M.,
Orchard, K.H., Cross, N.C., Harri-
son, C.J., and Ross, F.M.; UK
Myeloma Forum. (2009). Haemato-
logica 94, 1708–1713.
Fonseca, R., Bergsagel, P.L.,
Drach, J., Shaughnessy, J., Gutier-
rez, N., Stewart, A.K., Morgan, G.,
Van Ness, B., Chesi, M., Minvielle,
S., et al; International Myeloma
Working Group. (2009). Leukemia
23, 2210–2221.
Kapoor, P., Fonseca, R., Rajkumar,
S.V., Sinha, S., Gertz, M.A.,
Stewart, A.K., Bergsagel, P.L.,
Lacy, M.Q., Dingli, D.D., Ketterling,
R.P., et al. (2010). Mayo Clin. Proc.
85, 532–537.
Lode’, L., Eveillard, M., Trichet, V.,
Soussi, T., Wuilleme, S., Riche-
bourg, S., Magrangeas, F., Ifrah,
N., Campion, L., Traulle, C., et al.(2010). Haematologica, in press. Published online
July 15, 2010. 10.3324/haematol.2010.023697.
Mazars, G.R., Portier, M., Zhang, X.G., Jourdan,
M., Bataille, R., Theillet, C., and Klein, B. (1992).
Oncogene 7, 1015–1018.
Park, S.Y., Lee, J.H., Ha, M., Nam, J.W., and Kim,
V.N. (2009). Nat. Struct. Mol. Biol. 16, 23–29.
Pichiorri, F., Sung-Suk, S., Rocci, A., De Luca, L.,
Taccioli, C., Santhanam, R., Wenchao, Z., Benson,
D.M., Jr., Hofmainster, C., Alder, H., et al. (2010).
Cancer Cell 18, this issue, 367–381.
Tiedemann, R.E., Gonzalez-Paz, N., Kyle, R.A.,
Santana-Davila, R., Price-Troska, T., Van Wier,
S.A., Chng, W.J., Ketterling, R.P., Gertz, M.A.,
Henderson, K., et al. (2008). Leukemia 22, 1044–
1052.
Zhang, Y., Gao, J.S., Tang, X., Tucker, L.D., Ques-
enberry, P., Rigoutsos, I., and Ramratnam, B.
(2009). FEBS Lett. 583, 3725–3730.
